Abstract 39P
Background
This study aims to investigate the immunohistochemical expression of HIF-1α, GLUT1, and CA IX in patients with invasive ductal breast cancer (IDC) and assess their correlation with the maximum standardized uptake value of the primary tumor (pSUVmax) and other biological parameters. Additionally, the prognostic significance of pSUVmax, HIF-1α, GLUT1, and CA IX in predicting progression-free survival (PFS) will be evaluated.
Methods
A total of 174 female patients with IDC who underwent pretreatment F-18 FDG PET/CT were enrolled in this study. The pSUVmax was compared with clinicopathological parameters, including estrogen receptor (ER), progesterone receptor (PR), HER2 status, axillary lymph node metastasis (LNM), cancer stage, GLUT1, CA IX, and HIF-1α. The prognostic value of pSUVmax, GLUT1, CA IX, and HIF-1α for PFS was analyzed using the Kaplan-Meier method.
Results
The study revealed that pSUVmax was significantly higher in patients with HIF-1α≥2, GLUT1≥5, and CA IX≥3, compared to patients with HIF-1α<2, GLUT1<5, and CA IX<3 (4.9±4.1 vs. 3.9±3.2, P=0.02; 6.1±4.2 vs. 3.5±3.0, P=0.003; 5.9±4.5 vs. 3.8±3.2, P=0.003). Furthermore, patients with disease progression had significantly higher pSUVmax values than those who remained disease-free (6.4±3.5 vs. 4.1±3.6, P=0.0045). Receiver-operating characteristic (ROC) curve analysis identified optimal cutoff values for predicting PFS as pSUVmax of 6.8, GLUT1 of 5, and CA IX of 3, with corresponding sensitivities and specificities. Kaplan-Meier analysis revealed that pSUVmax ≥6.8 (P=0.0004), GLUT1≥5 (P=0.0005), and CA IX≥3 (P<0.0001) were predictive of recurrence.
Conclusions
The study findings indicate that pSUVmax on pretreatment F-18 FDG PET/CT can serve as a reliable surrogate marker for predicting progression in patients with IDC. Increased FDG uptake is associated with higher expression levels of HIF-1α, GLUT1, and CA IX, indicating the presence of glucose metabolism and hypoxia in breast cancer cells. These biomarkers hold promise for improved cancer detection and prognostication in IDC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
426P - Characterization of a novel comprehensive genomic profiling test with better detection of heterozygous deletions and gene fusions
Presenter: ryouta kakuta
Session: Poster Display
Resources:
Abstract
427P - Real-world performance of a comprehensive next-generation sequencing (NGS) panel for patients (pts) with solid tumors from Asia and the Middle East (AME)
Presenter: Nitesh Rohatgi
Session: Poster Display
Resources:
Abstract
428P - What do women want to see in a personalized breast cancer risk report? A qualitative study of Asian women of two countries
Presenter: Faustina Audrey Agatha
Session: Poster Display
Resources:
Abstract
429P - Clinical utility and outcomes of liquid biopsy-based next generation sequencing in identification of actionable genomic mutations in solid malignancy: A single center retrospective study in the Philippines
Presenter: Omar Maaño
Session: Poster Display
Resources:
Abstract
436P - Chemotherapy-induced hand-foot syndrome, comparative efficacy and safety of pharmacological prophylaxis: Systematic review and network meta-analysis
Presenter: Anand Srinivasan
Session: Poster Display
Resources:
Abstract
437P - A randomized single blinded phase II trial comparing efficacy and quality of life of topical aloe vera gel plus urea cream versus urea cream alone for prevention of hand-foot syndrome in cancer patients receiving capecitabine
Presenter: Lucksika Wanichtanom
Session: Poster Display
Resources:
Abstract
438P - A novel treatment for immune checkpoint inhibitor-related myocarditis
Presenter: Takahiro Niimura
Session: Poster Display
Resources:
Abstract
439P - Randomized controlled trial evaluating efficacy of topical urea-based cream for capecitabine-associated hand-foot syndrome prevention
Presenter: Concord Wongkraisri
Session: Poster Display
Resources:
Abstract
440P - Real-world adverse events of targeted therapy reported by pharmacist in oncology clinic
Presenter: TIKUMPORN PORNWISETSIRIKUL
Session: Poster Display
Resources:
Abstract
441P - The prophylactic efficacy of telpegfilgrastim, a Y-shape branched pegylated G-CSF in patient with chemotherapy-induced neutropenia: A multicenter, randomized phase III study
Presenter: Xinshuai Wang
Session: Poster Display
Resources:
Abstract